Real-world Effectiveness and Cost-effectiveness of Leading Inhaled Corticosteroids in Asthma Management
Status:
Completed
Trial end date:
2010-07-01
Target enrollment:
Participant gender:
Summary
The objective of the study was to compare the effectiveness, cost-effectiveness and direct
healthcare costs of managing asthma in patients with evidence of persistent asthma, following
the initiation and increased dose of inhaled corticosteroid (ICS) therapy using HFA-BDP
(Qvar®) (either as initial therapy or as a step-up therapy) compared with the most commonly
prescribed alternative ICS in the UK, CFC-beclometasone (BDP) and fluticasone (FP) as metered
dose inhalers (MDIs). Qvar vs FP analyses were split between adults (12-60yrs) and
paediatrics (5-11yrs).
Details
Lead Sponsor:
Research in Real-Life Ltd
Collaborators:
Teva Branded Pharmaceutical Products R&D, Inc. Teva Pharmaceutical Industries